IPHAInnate Pharma
$1.85
$0.0332
(1.82%)
Pre-Market
Reported EarningsMay 13
Mkt Cap$170.9M
Vol4.00
Fundamentals
Mkt Cap
$170.9M
Volume
-
52W High
$2.63
52W Low
$1.17
PE Ratio
-2.96
Avg. Volume
155,817.34
EPS (Annual)
-$0.6195
Rev/Employee
$19,296.61
Earnings
May 13
A Third Cancer Drug Just Entered the Clinic at an Under-$20-Million Company
A Third Cancer Drug Just Entered the Clinic at an Under-$20-Million Company A Third Cancer Drug Just Entered the Clinic at an Under-$20-Million Company PR Newswire SAN FRANCISCO, June 2, 2026 Equity Insider News CommentaryIssued on behalf of GT Biopharma, Inc. (NASDAQ: GTBP)SAN FRANCISCO, June 2...
PR Newswire
Outcome of Innate Pharmas 2026 Annual General Meeting
Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (Innate or the Company) announced the voting results of its shareholders at the Annual General Meeting (AGM), which took place on May 21, 2026, in Marseille. All resolutions were voted. A total of 94 votes were cast out of a...
Business Wire
Innate Pharma to participate in the Jefferies Global Healthcare Conference
Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (Innate or the Company), a clinical-stage biotechnology company developing immunotherapies for cancer patients, today announced...
Business Wire
Innate Pharma Reports First Quarter 2026 Business Update and Financial Results
Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (Innate or the Company) today reported its business update and consolidated financial results for the quarter ending March 31...
Business Wire
Number of Shares and Voting Rights of Innate Pharma as of April 16, 2026
Regulatory News: Pursuant to the article L. 233-8 II of the French Code de Commerce and the article 223-16 of the French stock-market authorities (Autorit des Marchs Financiers, or AMF) General Regulation, Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (Innate or the Company) releases its...
Business Wire
Innate Pharma (IPHA) Expected to Announce Quarterly Earnings on Wednesday
Innate Pharma (NASDAQ:IPHA) will be releasing its Q1 2026 TU earnings before the market opens on Wednesday, May 13. (View Earnings Report at...
MarketBeat
Innate Pharma Announces Conference Call and Webcast for Q1 2026 Business Update
Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (Innate or the Company), today announces that the Company will hold a conference call on Wednesday, May 13, 2026 at 1:30 p.m. CEST / 7:30 a.m. EDT, to provide an update on business progress for the first quarter of 2026...
Business Wire
Innate Pharma (NASDAQ:IPHA) Shares Down 0.7% - Here's What Happened
Innate Pharma (NASDAQ:IPHA) Stock Price Down 0.7% - Here's Why...
MarketBeat
Innate Pharma to Participate in the D. Boral Capital Global Conference
Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (Innate or the Company), a clinical-stage biotechnology company developing immunotherapies for cancer patients, today announced that members of its executive team will participate in one-on-one investor meetings at the following...
Business Wire
Innate Pharma to Present MATISSE Phase 2 Interim Results of IPH5201 in Clinical Trials Plenary Session at AACR 2026
Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (Innate or the Company), today announced that interim results from the MATISSE Phase 2 study evaluating IPH5201 in combination...
Business Wire
<
1
2
...
>